Clobetasol Propionate Shampoo, 0.05%, is a super-high potent topical corticosteroid formulation indicated for the treatment of moderate to severe forms of scalp psoriasis in subjects 18 years of age and older. Treatment should be limited to 4 consecutive weeks. The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per week. Patients should be instructed to use Clobetasol Propionate Shampoo, 0.05%, for th...
Clobetasol Propionate Shampoo, 0.05% is for topical use only, and not for ophthalmic, oral or intravaginal use. Clobetasol Propionate Shampoo, 0.05%, should be applied onto dry (not wet) scalp once a day in a thin film to the affected areas only, and left in place for 15 minutes before lathering and rinsing. The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per week. Move the hair away from the scalp...
Clobetasol Propionate Shampoo, 0.05%, is a translucent, colorless to pale yellow viscous liquid, supplied in 4 fl. oz. (118 mL) bottles. NDC 0781-7137-04 Storage: Keep tightly closed. Store at USP controlled room temperature 68˚ to 77˚F (20˚ - 25˚C), with excursions permitted between 59˚ and 86˚F (15˚ - 30˚C).
www.fda.gov/medwatchClobetasol Propionate Shampoo, 0.05%, is a super-high potent topical corticosteroid formulation indicated for the treatment of moderate to severe forms of scalp psoriasis in subjects 18 years of age and older. Treatment should be limited to 4 consecutive weeks. The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per week.
Patients should be instructed to use Clobetasol Propionate Shampoo, 0.05%, for the minimum time period necessary to achieve the desired results [see Dosage and Administration (2)].
Use in patients younger than 18 years of age is not recommended due to numerically high rates of hypothalamic-pituitary-adrenal (HPA) axis suppression [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4)].
Clobetasol Propionate Shampoo, 0.05%, should not be used on the face, groin or axillae. Avoid any contact of the drug product with the eyes and lips. In case of contact, rinse thoroughly with water all parts of the body that came in contact with the shampoo.
Clobetasol Propionate Shampoo, 0.05% is for topical use only, and not for ophthalmic, oral or intravaginal use.
Clobetasol Propionate Shampoo, 0.05%, should be applied onto dry (not wet) scalp once a day in a thin film to the affected areas only, and left in place for 15 minutes before lathering and rinsing.
The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per week.
Move the hair away from the scalp so that one of the affected areas is exposed. Position the bottle over the lesion. Apply a small amount of the shampoo directly onto the lesion, letting the product naturally flow from the bottle (gently squeeze the bottle), avoiding any contact of the product with the facial skin, eyes or lips. In case of contact, rinse thoroughly with water. Spread the product so that the entire lesion is covered with a thin uniform film. Massage gently into the lesion and repeat for additional lesion(s). Wash your hands after applying Clobetasol Propionate Shampoo, 0.05%.
Leave the shampoo in place for 15 minutes, then add water, lather and rinse thoroughly all parts of the scalp and body that came in contact with the shampoo (e.g., hands, face, neck and shoulders). Avoid contact with eyes and lips. Minimize contact to non-affected areas of the body. Although no additional shampoo is necessary to cleanse your hair, you may use a non-medicated shampoo if desired.
Treatment should be limited to 4 consecutive weeks. As with other corticosteroids, therapy should be discontinued when control is achieved. If complete disease control is not achieved after 4 weeks of treatment with Clobetasol Propionate Shampoo, 0.05%, treatment with a less potent topical steroid may be substituted. If no improvement is seen within 4 weeks, reassessment of the diagnosis may be necessary.
Clobetasol Propionate Shampoo, 0.05%, should not be used with occlusive dressings (shower cap or bathing cap) unless directed by a physician.
Shampoo, 0.05%, w/w. Each gram of Clobetasol Propionate Shampoo, 0.05%, contains 0.5 mg of clobetasol propionate in a translucent, colorless to pale yellow viscous liquid.
None
Clobetasol propionate is a highly potent topical corticosteroid that has been shown to suppress the HPA axis at the lowest doses tested.
Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid.
The effect of Clobetasol Propionate Shampoo, 0.05% on HPA axis suppression was evaluated in one trial in adolescents 12 to 17 years of age. In this trial, 5 of 12 evaluable subjects developed suppression of their HPA axis following 4 weeks of treatment with Clobetasol Propionate Shampoo, 0.05% applied once daily for 15 minutes to a dry scalp before lathering and rinsing.
Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include the use of more potent steroids, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure.
An adrenocorticotropic hormone (ACTH) stimulation test may be helpful in evaluating patients for HPA axis suppression. If HPA axis suppression is documented, an attempt should be made to gradually withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids.
Cushing’s syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids.
Use of more than one corticosteroid-containing product at the same time may increase the total systemic exposure.
Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios [see Use in Specific Populations (8.4)].
If irritation develops, Clobetasol Propionate Shampoo, 0.05%, should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation. Clinical diagnosis of allergic contact dermatitis can be confirmed with patch testing.
In the presence of dermatologic infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, use of Clobetasol Propionate Shampoo, 0.05%, should be discontinued until the infection has been adequately controlled.
Local adverse reactions may be more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids.
Reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria. Some local adverse reactions may be irreversible. Clobetasol propionate is not recommended in patients with acne vulgaris, rosacea or perioral dermatitis.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In clinical trials with Clobetasol Propionate Shampoo, 0.05%, the following adverse reactions have been reported: headache, burning/stinging, pruritus, edema, folliculitis, acne, dry skin, irritant dermatitis, alopecia, urticaria, skin atrophy and telangiectasia.
Table 1 summarizes selected adverse reactions that occurred in at least 1% of subjects in the Phase 2 and 3 studies for scalp psoriasis.
| Body System | Clobetasol Propionate Shampoo, 0.05% N=558 | Vehicle Shampoo N=127 |
| Skin and Appendages | 49 (8.8%) | 28 (22.0%) |
| Discomfort Skin | 26 (4.7%) | 16 (12.6%) |
| Pruritus | 3 (0.5%) | 9 (7.1%) |
| Body as A Whole | 33 (5.9%) | 12 (9.4%) |
| Headache | 10 (1.8%) | 1 (0.8%) |
Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified during post-approval use of Clobetasol Propionate Shampoo, 0.05%.
Teratogenic effects: Pregnancy Category C.
There are no adequate and well-controlled studies in pregnant women. Therefore, Clobetasol Propionate Shampoo, 0.05% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application to laboratory animals.
Clobetasol propionate is absorbed percutaneously, and when administered subcutaneously it was a significant teratogen in both the rabbit and the mouse.
Clobetasol propionate has greater teratogenic potential than steroids that are less potent.
The effect of clobetasol propionate on pregnancy outcome and development of offspring was studied in the rat. Clobetasol propionate was administered subcutaneously to female rats twice daily (0, 12.5, 25, and 50 µg/kg/day) from day 7 of presumed gestation through day 25 of lactation or day 24 presumed gestation for those rats that did not deliver a litter. The maternal no-observed-effect-level (NOEL) for clobetasol propionate was less than 12.5 μg/kg/day due to reduced body weight gain and feed consumption during the gestation period. The reproductive NOEL in the dams was 25 μg/kg/day (ratio of animal dose to proposed human dose of 0.07 on a mg/m2/day basis) based on prolonged delivery at a higher dose level. The no-observed-adverse-effect-level (NOAEL) for viability and growth in the offspring was 12.5 μg/kg/day (ratio of animal dose to proposed human dose of 0.03 on a mg/m2/day basis) based on incidence of stillbirths, reductions in pup body weights on days 1 and 7 of lactation, increased pup mortality, increases in the incidence of umbilical hernia, and increases in the incidence of pups with cysts on the kidney at higher dose levels during the preweaning period. The weights of the epididymides and testes were significantly reduced at higher dosages. Despite these changes, there were no effects on the mating and fertility of the offspring.
Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Clobetasol Propionate Shampoo, 0.05%, is administered to a nursing woman.
Use of Clobetasol Propionate Shampoo, 0.05%, in patients under 18 years old is not recommended due to potential for HPA axis suppression [see Warnings and Precautions (5.1)]
The effect of Clobetasol Propionate Shampoo, 0.05%, on HPA axis suppression was evaluated in one trial in adolescents 12 to 17 years of age with moderate to severe scalp psoriasis with involvement of at least 25% of the scalp. In this trial, 5 of 12 evaluable subjects developed suppression of their HPA axis following 4 weeks of treatment with Clobetasol Propionate Shampoo, 0.05%, applied once daily for 15 minutes to a dry scalp before lathering and rinsing. Only 1 of the 5 subjects who had suppression was tested for recovery of HPA axis, and this subject recovered after 2 weeks.
No studies have been performed in patients under the age of 12. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing’s syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during and/or after withdrawal of treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. Therefore, use is not recommended in patients under the age of 18.
HPA axis suppression, Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
Clinical studies of Clobetasol Propionate Shampoo, 0.05%, did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. In general, dose selection for an elderly patient should be made with caution, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.
Topically applied, Clobetasol Propionate Shampoo, 0.05%, can be absorbed in sufficient amounts to produce systemic effects [see Warnings and Precautions (5.1)]
Clobetasol Propionate Shampoo, 0.05%, contains clobetasol propionate, a synthetic fluorinated corticosteroid, for topical use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents.
The chemical name of clobetasol propionate is 21-chloro-9-fluoro-11β, 17-dihydroxy-16β-methylpregna-1, 4-diene-3, 20-dione 17-propionate.
It has the following structural formula:
Clobetasol propionate has a molecular weight of 466.97 (CAS Registry Number 25122-46-7). The molecular formula is C25H32CIFO5. Clobetasol propionate is a white to practically white crystalline, odorless powder insoluble in water.
Each gram of Clobetasol Propionate Shampoo, 0.05%, contains 0.5 mg of clobetasol propionate in a translucent, colorless to pale yellow viscous liquid shampoo base consisting of alcohol, citric acid, coco-betaine, polyquaternium-10, purified water, sodium citrate, and sodium laureth sulfate.
Like other topical corticosteroids, Clobetasol Propionate Shampoo, 0.05%, has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
Vasoconstrictor Assay
Clobetasol Propionate Shampoo, 0.05%, is in the super-high range of potency as demonstrated in vasoconstrictor studies in healthy subjects when compared with other topical corticosteroids. However, similar blanching scores do not necessarily imply therapeutic equivalence.
Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression
In studies evaluating the potential for hypothalamic-pituitary-adrenal (HPA) axis suppression, use of Clobetasol Propionate Shampoo, 0.05%, resulted in demonstrable HPA axis suppression in 5 out of 12 (42%) adolescent subjects [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4)].
The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle, the integrity of the epidermal barrier and occlusion.
Topical corticosteroids can be absorbed from normal intact skin. Inflammation and other disease processes in the skin may increase percutaneous absorption.
There are no human data regarding the distribution of corticosteroids to body organs following topical application. Nevertheless, once absorbed through the skin, topical corticosteroids are handled through metabolic pathways similar to systemically administered corticosteroids. They are metabolized, primarily in the liver, and are then excreted by the kidneys. In addition, some corticosteroids and their metabolites are also excreted in the bile.
Clobetasol propionate was not carcinogenic to rats when topically applied for 2 years at concentrations up to 0.005% which corresponded to doses up to 11 µg/kg/day (ratio of animal dose to proposed human dose of 0.03 on a mg/m2/day basis).
Clobetasol propionate at concentrations up to 0.001% did not increase the rate of formation of ultra violet light-induced skin tumors when topically applied to hairless mice 5 days per week for a period of 40 weeks.
Clobetasol propionate was negative in the in vitro mammalian chromosomal aberration test and in the in vivo mammalian erythrocyte micronucleus test.
The effect of subcutaneously administered clobetasol propionate on fertility and general reproductive toxicity was studied in rats at doses of 0, 12.5, 25, and 50 µg/kg/day. Males were treated beginning 70 days before mating and females beginning 15 days before mating through day 7 of gestation. A dosage level of less than 12.5 µg/kg/day clobetasol propionate was considered to be the no-observed-effect-level (NOEL) for paternal and maternal general toxicity based on decreased weight gain and for male reproductive toxicity based on increased weights of the seminal vesicles. The female reproductive NOEL was 12.5 µg/kg/day (ratio of animal dose to proposed human dose of 0.03 on a mg/m2/day basis) based on reduction in the numbers of estrous cycles during the pre-cohabitation period and an increase in the number of nonviable embryos at higher doses.
The safety and efficacy of Clobetasol Propionate Shampoo, 0.05%, have been evaluated in two clinical trials involving 290 subjects with moderate to severe scalp psoriasis. In both trials, subjects were treated with either Clobetasol Propionate Shampoo or the corresponding vehicle applied once daily for 15 minutes before lathering and rinsing for a period of 4 weeks. Efficacy results are presented in Table 2 below.
| Table 2: Efficacy Results | Clobetasol Propionate Shampoo, 0.05% N (%) | Shampoo Vehicle N (%) | ||
| Study A | Study B | Study A | Study B | |
| Total Number of Subjects | 95 | 99 | 47 | 49 |
| Success Rate1 at Endpoint2 | 40 (42.1%) | 28 (28.3%) | 1 (2.1%) | 5 (10.2%) |
| Subjects with Scalp Psoriasis Parameter Clear (None) at Endpoint Erythema3 Scaling3 Plaque Thickening3 | 17 (17.9%) 21 (22.1%) 35 (36.8%) | 12 (12.1%) 15 (15.2%) 34 (34.3%) | 3 (6.4%) 0 (0%) 5 (10.6%) | 1 (2.0%) 2 (4.1%) 5 (10.2%) |
1Success rate defined as the proportion of subjects with a-0 (clear) or 1 (minimal) on a 0 to 5 point physician's Global Severity Scale for scalp psoriasis.
2At four (4) weeks or last observation recorded for a subject during the treatment period (baseline if no post-baseline data were available).
3Subjects with 0 (clear) on a 0 to 3 point scalp psoriasis parameter scale.
Clinical studies of Clobetasol Propionate Shampoo, 0.05%, did not include sufficient numbers of non-Caucasian subjects to determine whether they respond differently than Caucasian subjects with regards to efficacy and safety.
Clobetasol Propionate Shampoo, 0.05%, is a translucent, colorless to pale yellow viscous liquid, supplied in 4 fl. oz. (118 mL) bottles.
NDC 0781-7137-04
Storage: Keep tightly closed. Store at USP controlled room temperature 68˚ to 77˚F (20˚ - 25˚C), with excursions permitted between 59˚ and 86˚F (15˚ - 30˚C).
See FDA-approved patient labeling (Patient Information)
Information for Patients
Inform the patient using topical corticosteroids to adhere to following instructions:
Patient Information
Clobetasol Propionate
Shampoo
Important: For use on the scalp only. Do not get Clobetasol Propionate Shampoo near or in your eyes, mouth or vagina.
Read the Patient Information that comes with Clobetasol Propionate Shampoo before you start using it and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.
What is Clobetasol Propionate Shampoo?
You should not use Clobetasol Propionate Shampoo:
Clobetasol Propionate Shampoo should not be used in children under 18 years of age.
What should I tell my doctor before using Clobetasol Propionate Shampoo?
Before you use Clobetasol Propionate Shampoo, tell your doctor if you:
Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Especially tell your doctor if you take other corticosteroid medicines by mouth or use other products on your skin that contain corticosteroids. You should not use other products that contain corticosteroids while you are using Clobetasol Propionate Shampoo. Ask your doctor or pharmacist if you are not sure.
Know the medicines you take. Keep a list of them to show your doctor and pharmacist if you get a new medicine.
How should I use Clobetasol Propionate Shampoo?
See the “Instructions for Use” at the end of the Patient Information for detailed information about the right way to use Clobetasol Propionate Shampoo.
What are the possible side effects of Clobetasol Propionate Shampoo?
Clobetasol Propionate Shampoo can pass through your skin. Too much Clobetasol Propionate Shampoo passing through your skin can cause your adrenal glands to stop working. Your doctor may do blood tests to check how well your adrenal glands are working.
The most common side effects of Clobetasol Propionate Shampoo include:
If you go to another doctor for illness, injury or surgery, tell that doctor that you are using Clobetasol Propionate Shampoo.
Tell your doctor if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Clobetasol Propionate Shampoo. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
You may also report side effects to Sandoz Inc. at 1-800-525-8747.
How should I store Clobetasol Propionate Shampoo?
Keep Clobetasol Propionate Shampoo and all medicines out of the reach of children.
General information about Clobetasol Propionate Shampoo
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Clobetasol Propionate Shampoo for a condition for which it was not prescribed. Do not give Clobetasol Propionate Shampoo to other people, even if they have the same symptoms that you have. It may harm them.
This Patient Information leaflet summarizes the most important information about Clobetasol Propionate Shampoo. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about Clobetasol Propionate Shampoo that is written for health professionals.
What are the ingredients in Clobetasol Propionate Shampoo?
Active ingredient: clobetasol propionate
Inactive ingredients (shampoo base): alcohol, citric acid, coco-betaine, polyquaternium-10, purified water, sodium citrate and sodium laureth sulfate.
Instructions for Use
Clobetasol Propionate
Shampoo
Important: For use on the scalp only. Do not get Clobetasol Propionate Shampoo near or in your eyes, mouth or vagina.
Read the Instructions for Use that comes with Clobetasol Propionate Shampoo before you start using it and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.
How to apply Clobetasol Propionate Shampoo to your scalp:
Your hair should be dry when you apply Clobetasol Propionate Shampoo to your scalp.
Do not get Clobetasol Propionate Shampoo on your face, in your eyes or on your lips. If Clobetasol Propionate Shampoo does get on these areas, rinse well with water.
Step 1: To apply Clobetasol Propionate Shampoo to your scalp, part your hair at the area where it is to be applied.
Step 2: Hold the bottle of Clobetasol Propionate Shampoo over the affected area. Gently squeeze the bottle and apply a small amount of shampoo to the affected area.
Step 3: Gently rub Clobetasol Propionate Shampoo into the affected area so that only the affected area is covered with a thin, even layer of Clobetasol Propionate Shampoo.
Step 4: Repeat Steps 1 through 3 to apply Clobetasol Propionate Shampoo to other affected areas on your scalp as instructed by your doctor.
Step 5: Wash your hands after applying Clobetasol Propionate Shampoo.
Step 6:
Leave Clobetasol Propionate Shampoo on your scalp for 15 minutes. You should not bandage or cover your head with a shower cap, bathing cap, or a towel while Clobetasol Propionate Shampoo is on your scalp, unless your doctor tells you to.
Step 7: After 15 minutes have passed, wet your hair with water. Lather and rinse your hair and scalp completely. Rinse any other parts of your body that come into contact with Clobetasol Propionate Shampoo, such as your hands, face, neck and shoulders.
No other shampoo is needed, but you may wash your hair with a non-medicated shampoo after using Clobetasol Propionate Shampoo.
This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.
Manufactured by:
G Production Inc.
Baie d’Urfé, QC, H9X 3S4 Canada for
Sandoz Inc.
Princeton, NJ 08540
Made in Canada
P51964-1
NDC 0781-7137-04
Clobetasol
Propionate
Shampoo
0.05 %
Rx only
4 fl. oz. (118 mL)
SANDOZ
a Novartis company
For External Use Only.
Not for Ophthalmic Use.
Usual dosage: Apply a thin film to affected areas of the scalp and leave in place for 15 minutes before lathering and rinising. Do not apply Clobetasol Propionate Shampoo, 0.05% to the face, underarms or groin, and avoid contact with eyes and lips. Do not use for longer than 4 weeks. See package insert for complete prescribing information. See carton closure for lot number and expiration date.
Each mL contains:
Active ingredient: clobetasol propionate 0.05%
Excipients: alcohol, citric acid, coco-betaine, poly-quaterniumn-10, purified water, sodium citrate, and sodium laureth sulfate.
Storage: Keep tightly closed. Store at controlled room temperature 68° to 77°F (20° - 25°C) with excursions permitted between 59° - 86°F (15° - 30°C).
Marketed by:
Sandoz Inc.
Princeton, NJ 08540
Made in Canada
P51963-2
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0781-7137-04 | ML - Milliliter | 0781-7137 | 08d0f3c8-1ad5-4dd9-b1c8-7c5c624a361f | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CLOBETASOL PROPIONATE | ACTIVE INGREDIENT | 779619577M | 4 | |
| CLOBETASOL | ACTIVE MOIETY | ADN79D536H | 4 | |
| ALCOHOL | INACTIVE INGREDIENT | 3K9958V90M | 4 | |
| CITRIC ACID MONOHYDRATE | INACTIVE INGREDIENT | 2968PHW8QP | 4 | |
| COCO-BETAINE | INACTIVE INGREDIENT | 03DH2IZ3FY | 4 | |
| POLYQUATERNIUM-10 (400 MPA.S AT 2%) | INACTIVE INGREDIENT | HB1401PQFS | 4 | |
| SODIUM CITRATE | INACTIVE INGREDIENT | 1Q73Q2JULR | 4 | |
| SODIUM LAURETH-3 SULFATE | INACTIVE INGREDIENT | BPV390UAP0 | 4 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0781-7137 | 0781-7137-04 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CLOBETASOL PROPIONATE | 779619577M | ACTIB |
| ALCOHOL | 3K9958V90M | IACT |
| COCO-BETAINE | 03DH2IZ3FY | IACT |
| POLYQUATERNIUM-10 (400 MPA.S AT 2%) | HB1401PQFS | IACT |
| CITRIC ACID MONOHYDRATE | 2968PHW8QP | IACT |
| WATER | 059QF0KO0R | IACT |
| SODIUM CITRATE | 1Q73Q2JULR | IACT |
| SODIUM LAURETH-3 SULFATE | BPV390UAP0 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | DOUCHE / VAGINAL | 0.07 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LOTION / TOPICAL | 25 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CREAM / VAGINAL | 0.49 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | MOUTHWASH / BUCCAL | 200 mg/1ml | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | OINTMENT / TOPICAL | 1 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SUSPENSION / RECTAL | 0.35 %v/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | DROPS / ORAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 385 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / SUBCUTANEOUS | 26 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION, CONCENTRATE / INTRAVENOUS | NA | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION, SOLUTION / SUBCUTANEOUS | 6.1 %v/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL / TOPICAL | 9971 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, METERED / RESPIRATORY (INHALATION) | 26664 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SPRAY, METERED / NASAL | 2 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | EMULSION / TOPICAL | 0.11 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, FOAM / TOPICAL | 4504 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL / NASAL | 20 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / RESPIRATORY (INHALATION) | 0.08 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYRUP / ORAL | 722 mg/5ml | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / NASAL | 2.8 mg/1ml | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INFILTRATION | 0.02 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / TOPICAL | 17 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL, METERED / TOPICAL | 541 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 608 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SUSPENSION / ORAL | 840 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | POWDER, FOR SOLUTION / TOPICAL | 40 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, EFFERVESCENT / ORAL | 460 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SHAMPOO / TOPICAL | 17 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / RESPIRATORY (INHALATION) | 8 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOAP / TOPICAL | 0.5 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYSTEM / IONTOPHORESIS | 0.2 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / OPHTHALMIC | 0.5 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION / INTRAVASCULAR | 100 %v/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / AURICULAR (OTIC) | 0.2 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / ORAL | 3563 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION/ DROPS / ORAL | 19 mg | ||
| SODIUM LAURETH-3 SULFATE | SODIUM LAURETH-3 SULFATE | BPV390UAP0 | SHAMPOO / TOPICAL | 3192 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / SOFT TISSUE | ADJ PH | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SHAMPOO / TOPICAL | 714 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SWAB / TOPICAL | 0.05 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | LOTION / TOPICAL | 0.85 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / INTRAVENOUS | 400 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | AEROSOL, FOAM / TOPICAL | 1 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION/ DROPS / AURICULAR (OTIC) | 0.04 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL / RECTAL | 898 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY / TRANSDERMAL | 90 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET / SUBLINGUAL | 24 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SOLUTION / TOPICAL | NA | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SWAB / TOPICAL | 2250 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION / ORAL | 269 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRAVENOUS | 2068 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION/ DROPS / OPHTHALMIC | 0.05 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRAMUSCULAR | 28 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | GEL / TOPICAL | 1 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / RESPIRATORY (INHALATION) | 5 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER / ORAL | 840 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION/ DROPS / TOPICAL | 0.01 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL / DENTAL | 1.8 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY / TOPICAL | 3633 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / OPHTHALMIC | 0.03 %w/v |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021644-001 | CLOBEX | CLOBETASOL PROPIONATE | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 |
| Application-product | TE code |
|---|---|
| N021644-001 | AB |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N021644-001 | CLOBEX | 0.05% | SHAMPOO / TOPICAL | AB | RLD, RS | 2004-02-05 | 3a93d1ddd44b… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N021644-001 | AB | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | N021644-001 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N021644-001 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N021644-001 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021644-001 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N021644-001 | AB | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021644-001 | AB | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N021644-001 | AB | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N021644-001 | AB | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N021644-001 | AB | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N021644-001 | AB | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N021644-001 | AB | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | N021644-001 | AB | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N021644-001 | AB | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N021644-001 | AB | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N021644-001 | AB | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | N021644-001 | AB | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021644-001 | AB | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N021644-001 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N021644-001 | AB | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | N021644-001 | AB | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | N021644-001 | AB | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | N021644-001 | AB | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N021644-001 | AB | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | N021644-001 | AB | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | N021644-001 | AB | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | N021644-001 | AB | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | N021644-001 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N021644-001 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N021644-001 | AB | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N021644-001 | AB | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | N021644-001 | AB | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | N021644-001 | AB | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N021644-001 | AB | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N021644-001 | AB | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N021644-001 | AB | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N021644-001 | AB | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | N021644-001 | AB | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | N021644-001 | AB | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N021644-001 | AB | 1 | 3a93d1ddd44b… |
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021644-001 | 7700081 | 2022-01-03 | U-1044 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | N021644-001 | 7700081 | 2022-01-03 | U-1044 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | N021644-001 | 7700081 | 2022-01-03 | U-1044 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | N021644-001 | 7316810 | 2019-06-17 | Drug product | 74a2ff9319b5… | ||
| 2019-12-13 00:20 UTC | 2019-12 | N021644-001 | 8066975 | 2019-06-17 | Drug product | 2011-12-05 | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N021644-001 | 8066976 | 2019-06-17 | Drug product | 2011-12-05 | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N021644-001 | 7700081 | 2022-01-03 | U-1044 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | N021644-001 | 7700081 | 2022-01-03 | U-1044 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | N021644-001 | 7700081 | 2022-01-03 | U-1044 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N021644-001 | 7700081 | 2022-01-03 | U-1044 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | N021644-001 | 7700081 | 2022-01-03 | U-1044 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | N021644-001 | 7700081 | 2022-01-03 | U-1044 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | N021644-001 | 7700081 | 2022-01-03 | U-1044 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | N021644-001 | 7316810 | 2019-06-17 | Drug product | 3f01610625f2… | ||
| 2019-12-14 00:12 UTC | 2019-12 | N021644-001 | 8066975 | 2019-06-17 | Drug product | 2011-12-05 | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N021644-001 | 8066976 | 2019-06-17 | Drug product | 2011-12-05 | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N021644-001 | 7700081 | 2022-01-03 | U-1044 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | N021644-001 | 7316810 | 2019-06-17 | Drug product | b00525d2431f… | ||
| 2019-09-15 20:21 UTC | 2019-09 | N021644-001 | 8066975 | 2019-06-17 | Drug product | 2011-12-05 | b00525d2431f… | |
| 2019-09-15 20:21 UTC | 2019-09 | N021644-001 | 8066976 | 2019-06-17 | Drug product | 2011-12-05 | b00525d2431f… | |
| 2019-09-15 20:21 UTC | 2019-09 | N021644-001 | 7700081 | 2022-01-03 | U-1044 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | N021644-001 | 7316810 | 2019-06-17 | Drug product | ea99ee380514… | ||
| 2019-07-19 19:46 UTC | 2019-07 | N021644-001 | 8066975 | 2019-06-17 | Drug product | 2011-12-05 | ea99ee380514… | |
| 2019-07-19 19:46 UTC | 2019-07 | N021644-001 | 8066976 | 2019-06-17 | Drug product | 2011-12-05 | ea99ee380514… | |
| 2019-07-19 19:46 UTC | 2019-07 | N021644-001 | 7700081 | 2022-01-03 | U-1044 | ea99ee380514… | ||
| 2023-01-26 05:58 UTC | 2023-01 | N021644-001 | 7700081 | 2022-01-03 | U-1044 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N021644-001 | 7700081 | 2022-01-03 | U-1044 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | N021644-001 | 7700081 | 2022-01-03 | U-1044 | f41ea6bd6efb… | ||
| 2022-09-29 23:25 UTC | 2022-09 | N021644-001 | 7700081 | 2022-01-03 | U-1044 | e64feba35796… | ||
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | N021644-001 | 7700081 | 2022-01-03 | U-1044 | cb3db0bc1861… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| dc343075-10a8-439d-9eb2-a2e760b402a9 | a4f82a4c-bc7e-4927-936e-add854812559 | 2020-08-20 | Warnings, Adverse reactions | dc343075-10a8-439d-9eb2-a2e760b402a9 a4f82a4c-bc7e-4927-936e-add854812559 |
Adverse event summaries are temporarily unavailable. Other product information remains available.